Neogen vs QuidelOrtho
NEOG and QDEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NEOG and QDEL compare
Neogen is the larger company, worth 2.8 times as much as QuidelOrtho ($2.6B against $909M).
Neogen grew revenue faster over the last twelve months (−0.33% versus −2.5% for QuidelOrtho).
Neogen keeps more of each dollar of sales as profit, with a net margin of −6.3% compared with −39.2% at QuidelOrtho.
Neogen scores higher on the StockData Score (7 against 6 for QuidelOrtho), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NEOG | QDEL |
|---|---|---|
| Size and price | ||
| Market cap | $2.6B | $909M |
| Share price | $11.82 | $13.25 |
| Change, 1 year | 89.7% | −52.6% |
| Change, 5 years | −73.9% | −89.1% |
| Beta (5Y) | 1.21 | 0.85 |
| Employees | 2,636 | 6,500 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 1 | 3 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 3 (better) | 2 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.9× | 0.3× (better) |
| P/B | 1.2× | 0.5× (better) |
| EV/EBITDA | 36.4× | – |
| P/FCF | 51.8× | – |
| FCF yield | 1.9% (better) | −23.2% |
| Fair value | $7.47 | $84.25 |
| Margin of safety | −58.3% | 84.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −0.33% (better) | −2.5% |
| Revenue growth, 5Y average | 13.2% (better) | 10.4% |
| Profitability | ||
| Gross margin | 47.4% (better) | 44.6% |
| Operating margin | −0.83% (better) | −30.8% |
| Net margin | −6.3% (better) | −39.2% |
| FCF margin | 5.6% (better) | −7.9% |
| Return on equity | −2.7% (better) | −45.9% |
| Return on invested capital | −0.17% (better) | −13.3% |
| Financial health | ||
| Debt / equity | 0.74 (better) | 1.63 |
| Net debt / EBITDA | 12.69 | – |
| Interest coverage | – | −4.1× |
| Current ratio | 3.90 (better) | 1.39 |
| Altman Z-score | 1.45 (better) | −0.08 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.57% |
| Shareholder yield | 0.00% (better) | −0.57% |
| Ownership | ||
| Held by institutions | 109% | 121% |
| Held by insiders | 0.55% | 43.4% |
| Insider net buying, 12 months | $7.5K | $1.2M (better) |
| Short interest, % of float | 5.5% | 38.5% |
Go deeper
- NEOG stock overview
- NEOG income statement
- NEOG valuation and score
- QDEL stock overview
- QDEL income statement
- QDEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.